HIND — Vyome Holdings, Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1427570 ·
Last close
$2.17
Market Cap
$15.23M
52W High
$2.50
52W Low
$1.81
ADV30
33,327
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 31,591 | 16,645 | -1,129,940 | -962,910 | 10,185,446 | 8,795,783 | 2,144,125 |
| Dec 2025 | 36,551 | 22,066 | -1,355,074 | -1,063,974 | 6,497,177 | 4,982,333 | 2,735,160 |
| Sep 2025 | 34,627 | 18,050 | -868,777 | -8,595,300 | 7,045,396 | 5,707,012 | 3,126,936 |
| Mar 2025 | 198,581 | 154,419 | -198,998 | -293,974 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,120,663
Investing CF
$1,797
Financing CF
$6,266,354
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.42
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-88,526,485
Inventory
—
Receivables
$140,843
ST Investments
—
EBIT TTM
$-11,057,114
Pretax Income TTM
$-11,154,475
Interest Exp TTM
$97,361
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$152,724
EBITDA
$-3,666,912
Free Cash Flow
$4,116,844
Enterprise Value
$7,754,318
Total Cash
$8,795,783
Total Debt
$22,548
Shares Out
7,018,528
Trailing EPS
$-1.56
Book Value
$0.96
ROE
-665.6%
ROA
-39.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 319,714 | -2,747,037 | -10,262,007 | 6,497,177 | 2,735,160 | — | -3,748,853 |
| Dec 2024 | 256,944 | -1,006,340 | -1,447,461 | 1,381,561 | 5,772,594 | — | -614,136 |
| Dec 2023 | 415,940 | -767,718 | -719,920 | 1,421,251 | 7,506,423 | — | -563,983 |
| Dec 2022 | 382,865 | -1,104,183 | -1,255,298 | 1,789,415 | 7,154,503 | — | -362,879 |
TTM Snapshot
Revenues TTM
$6,880,000
NetIncome TTM
$-24,881,000
OpCashFlow TTM
$0
Assets (Latest)
$20,393,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | $15.02M | $0.61 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $14.82M | $0.54 | — |
| INTI | Inhibitor Therapeutics, Inc. | $14.67M | $0.09 | — |
| SCNX | Scienture Holdings, Inc. | $14.64M | $0.36 | — |
| MBRX | Moleculin Biotech, Inc. | $14.46M | $2.71 | — |
News headlines (Yahoo Finance, 1h cache)
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
2026-05-28 12:00 · Yahoo
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
2026-05-12 12:00 · Yahoo
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
2026-04-22 12:00 · Yahoo
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
2026-04-06 12:00 · Yahoo
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
2026-03-30 23:00 · Yahoo
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
2026-03-26 12:00 · Yahoo
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
2026-02-24 13:00 · Yahoo
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
2026-02-18 14:00 · Yahoo
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
2026-02-11 12:00 · Yahoo
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
2026-02-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.